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Abstract
Introduction Fibroblast growth factor 8 (FGF8) is isolated as an
androgen-induced growth factor, and has recently been shown
to contribute to limb morphogenesis. The aim of the present
study was to clarify the role of FGF8 in animal models of
osteoarthritis (OA).
Methods The expression of FGF8 in the partial meniscectomy
model of OA in the rabbit knee was examined by
immunohistochemistry. The effect of intraperitoneal
administration of anti-FGF8 antibody was tested in a model of
OA that employed injection of monoiodoacetic acid or FGF8
into the knee joint of rats. The effect of FGF8 was also tested
using cultured chondrocytes. Rabbit articular chondrocytes
were treated with FGF8 for 48 hours, and the production of
matrix metalloproteinase and the degradation of sulfated
glycosaminoglycan in the extracellular matrix (ECM) were
measured.
Results The expression of FGF8 in hyperplastic synovial cells
and fibroblasts was induced in the meniscectomized OA model,
whereas little or no expression was detected in normal
synovium. Injection of FGF8 into rat knee joints induced the
degradation of the ECM, which was suppressed by anti-FGF8
antibody. In the monoiodoacetic acid-induced arthritis model,
anti-FGF8 antibody reduced ECM release into the synovial
cavity. In cultured chondrocytes, FGF8 induced the release of
matrix metalloproteinase 3 and prostaglandin E2, and caused
degradation of the ECM. The combination of FGF8 and IL-1α
accelerated the degradation of the ECM. Anti-FGF8 antibody
suppressed the effects of FGF8 on the cells.
Conclusion FGF8 is produced by injured synovium and
enhances the production of protease and prostaglandin E2 from
inflamed synoviocytes. Degradation of the ECM is enhanced by
FGF8. FGF8 may therefore participate in the degradation of
cartilage and exacerbation of osteoarthritis.
Introduction
Osteoarthritis (OA) is a degenerative disease and a major
cause of disability in humans. Aging, mechanical stress and
traumatic injury, genetic susceptibility, and metabolic predis-
position are considered risk factors for this disease. Degener-
ation is mainly characterized by the destruction of articular
cartilage, which is composed of abundant extracellular matrix
(ECM) that is rich in sulfated proteoglycan and type II collagen
[1]. In OA, synovitis is believed to be a reactive process as a
result of cartilage destruction and the release of ECM-degra-
dation products in the synovial fluid [1]. Loss of the ECM is
caused by the secretion of degradative enzymes from
chondrocytes in response to cytokines and prostaglandin E2
(PGE2) within the joint [1,2]. Matrix metalloproteinases
(MMPs) are implicated in the destruction of articular cartilage
in arthritis [3]. MMP-3 is believed to be a key enzyme involved
in the degradation of the ECM [4]. MMPs are produced as
proenzymes, which need to be activated by other enzymes
such as plasmin or already activated MMPs [5]. Levels of
proMMP-3 are reported to increase in joint injury and OA [6].
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Fibroblast growth factor (FGF) is a family of at least 24 growth-
regulatory proteins – sharing 35% to 50% amino acid
sequence identity – that have potent mitogenic effects on a
variety of cells of mesodermal and ectodermal origin [7,8].
FGF8 was originally isolated from the conditioned medium of
an androgen-dependent mouse mammary tumor cell line (SC-
3) as an androgen-induced growth factor, and was later clas-
sified as a member of the FGF family based on structural sim-
ilarity [9]. Alternative splicing of the FGF8 gene potentially
gives rise to eight different protein isoforms (FGF8a to FGF8h)
in mice, and to four isoforms (FGF8a, FGF8b, FGF8e, and
FGF8f) in humans [10,11]. FGF8b has the highest capacity
among these isoforms on NIH3T3 cell transformation [12].
FGF signaling is transduced through the formation of a com-
plex of a growth factor, a proteoglycan, and a high-affinity
fibroblast growth factor receptor (FGFR), which is a trans-
membrane tyrosine kinase receptor [13]. Four different high-
affinity receptors (FGFR1, FGFR2, FGFR3, and FGFR4) bind
FGF ligands and display varying patterns of expression [14].
Extracellular domains of FGFRs consist of three immunoglob-
ulin-like loops (loop I, loop II, and loop III). Alternative mRNA
splicing of loop III of FGFR1 to FGFR3 leads to distinct func-
tional variants (IIIb and IIIc) that have different ligand-binding
specificities and affinities.
FGF8 can bind to three receptors – FGFR2IIIc, FGFR3IIIc,
and FGFR4 [15] – and has an important role in embryogenesis
and morphogenesis [16]. FGF8 is expressed during gastrula-
tion and is involved in the process of limb and facial morpho-
genesis in mice [17] and in chicks [18]. In the complete
absence of both FGF4 and FGF8, limb development fails [19].
FGF8 may also be involved in ectopic bone and cartilage for-
mation by breast cancer cells that produce high amounts of
FGF8 [20]. In addition, expression of FGF8 mRNA in the syn-
ovial sarcoma cell line has been reported [21]. The function of
FGF8 in OA has not yet been characterized.
Treatment of OA patients is aimed at controlling pain, improv-
ing function, and reducing disability. The most common phar-
macologic therapeutic agents used currently are analgesics,
which include nonsteroidal antiinflammatory drugs and
hyaluronic acid, but these drugs do not prevent the develop-
ment and progression of OA.
The purpose of the present study was to examine whether
FGF8 is involved in the destruction of cartilage in OA models.
Initially, a rabbit meniscectomy model of OA, in which typical
degenerative changes are observed in the operated knee
joints [22,23], was used to detect the expression of FGF8.
The activities of FGF8 were studied in vitro using cultures of
rabbit articular chondrocytes. We also examined a neutralizing
monoclonal anti-FGF8 antibody [24,25] to prevent the pro-
gression of cartilage degradation in the rat OA model, which
was induced by the injection of monoiodoacetic acid (MIA)
into the joint [26].
Materials and methods
Materials
Recombinant human FGF8 was purchased from PeproTech
(Rocky Hill, NJ, USA). The anti-FGF8 neutralizing antibody,
KM1334, was prepared as described previously [24,25].
KM1334 recognized FGF8b and FGF8f specifically out of the
four human FGF8 isoforms, and showed little binding to other
members of the FGF family. Neutralizing activity of KM1334
was shown by the blocking of FGF8b binding to its receptors.
KM1334 neutralizes the activity of human FGF8, rabbit FGF8,
and rat FGF8.
Animals
All procedures were approved by the Institutional Review
Board. Male New Zealand white rabbits were purchased from
Kitayama Labes (Nagano, Japan). Male Sprague–Dawley rats
were purchased from Charles River Japan (Kanagawa, Japan).
All animals were kept in a specific pathogen-free animal facility
at a temperature of 22 to 24°C, a humidity of 50% to 60%, and
with a 12-hour day/night cycle.
Partial meniscectomy model in the rabbit knee
Six male rabbits (2 to 2.5 kg) were anesthetized by intramus-
cular injection of ketamine (15 mg/kg) and xylazine (2 mg/kg).
Each animal was subjected to section of the fibular collateral
and sesamoid ligaments of the left knee and the resection of a
3 to 4 mm segment (approximately 30% to 40%) of the lateral
meniscus (the meniscectomized group) according to previous
reports [22,23]. In four additional animals, the ligaments were
resected and the joint space of the left knee was exposed
without subsequent partial meniscectomy as a sham opera-
tion. Two weeks after the surgery, the rabbits were killed by an
intravenous overdose of anesthetic.
Histological evaluation was performed on sections of the syn-
ovia and articular cartilage from meniscectomized knees, from
sham-operated knees (the sham group), and from nonop-
erated knees of the sham group (the normal group). Speci-
mens were fixed in 10% formalin, decalcified, and embedded
in paraffin. Four-micrometer sections were prepared and
stained with H&E or safranin O, and were subjected to immu-
nohistochemistry for FGF8. Histopathology of the synovial
membranes of the knee joints were evaluated using the spec-
imens stained with H&E.
Serial sections were subjected to immunohistochemistry for
FGF8. These sections were treated with primary antibody
(anti-FGF8 antibody KM1334 or mouse IgG1, 2.7 μg/ml in
PBS without calcium and magnesium containing 1% BSA)
overnight at 4°C and were washed with PBS without calcium
and magnesium containing 1% BSA. Secondary antibody
(horseradish peroxidase-labeled anti-mouse IgG rabbitAvailable online http://arthritis-research.com/content/10/4/R90
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polyclonal antibody (Dako Japan, Kyoto, Japan) diluted 1:200
in PBS without calcium and magnesium containing 1% BSA)
was then added and incubation continued for 60 minutes at
room temperature. Finally, the sections were washed, devel-
oped using diaminobenzidine, and were counterstained with
hematoxylin.
The presence of proteoglycan in cartilage was assessed using
the specimens stained with safranin O–fast green. The articu-
lar cartilage was graded according to the modified Mankin
scale, as described elsewhere [27]. Histological evaluations
were performed in a blinded manner using the following crite-
ria: grade 0, normal; grade 1+, very slight; grade 2+, slight;
grade 3+, moderate; and grade 4+, marked.
Cell culture
Articular chondrocytes were isolated from the shoulder and
knee joints of 3-week-old rabbits as previously described [28].
Cartilage was digested with 0.4% actinase E (Kaken Pharma-
ceuticals, Tokyo, Japan) for 1 hour at 37°C, followed by
0.025% collagenase P (Roche Diagnostics, Basel, Switzer-
land) for 5 hours at 37°C. The viability of the harvested cells as
assessed by trypan blue exclusion was always >95%. The
chondrocytes were then suspended in DMEM (Invitrogen,
Carlsbad, CA, USA) with 10% FBS (Intergen, Purchase, NY,
USA) and antibiotics (100 U/ml penicillin and 0.1 mg/ml strep-
tomycin; Invitrogen). The chondrocytes were cultured in each
well of 24-well tissue culture plates at a density of 1 × 105
cells/ml under 5% carbon dioxide–95% air at 37°C. Primary
cultures maintained in a monolayer were used for all the
experiments.
Synovial cells were collected from the knee joints of 3-week-
old rabbits by the method of Hamilton and Slywka [29]. The
cells were suspended in 10% FBS/DMEM with antibiotics in
80 cm2 bottle flasks.
Degradation of the extracellular matrix in chondrocyte 
cultures
After the chondrocytes reached confluence, the culture
medium was replaced with 0.5% FBS/DMEM, followed by cul-
turing for 24 hours. The culture medium was removed, and
cells were incubated with 1 ml of 0.5% FBS/DMEM in the
presence of FGF8 and/or recombinant human IL-1α (R&D
Systems, Minneapolis, MN, USA) with various concentrations
of anti-FGF8 antibody. A concentration of FGF8 (100 ng/ml)
that caused ECM degradation was used. FGF8 at 10 ng/ml
did not induce ECM degradation. A low concentration (0.01
ng/ml) of IL-1α that showed no effect by itself on ECM degra-
dation was used. After 48 hours of incubation, the concentra-
tions of proMMP-3 and PGE2 in the culture supernatant were
measured using commercially available kits – proMMP-3
(Amersham Pharmacia Biotech, Piscataway, NJ, USA) and
PGE2 (Cayman Chemical, Ann Arbor, MI, USA). The amount of
sulfated glycosaminoglycan (S-GAG) in the ECM remaining
on the plate was measured using 1,9-dimethylmethylene blue
(Sigma-Aldrich, St Louis, MO, USA) as previously described
[30].
Growth of synovial cells
Rabbit synovial cells were collected by trypsin treatment, sus-
pended in 10% FBS/RPMI 1640 medium, and cultured in
each well of 96-well tissue culture plates at a density of
10,000 cells/well under 5% carbon dioxide–95% air at 37°C.
After 24 hours the culture medium of each well was removed,
and then 0.2% FBS/RPMI 1640 medium (200 μl) with or with-
out FGF8 and/or various concentrations of anti-FGF8 anti-
body were added to the cells. After 48 hours, 9.25 kBq methyl
[3H]thymidine (Amersham Pharmacia Biotech) was added to
each well. The radioactivity of [3H]thymidine incorporated into
the cells was measured 24 hours after the incubation using a
liquid scintillation counter (1205 Beta Plate; Perkin Elmer
Japan, Kanagawa, Japan).
Intraarticular injection of FGF8 in rats
Arthritis-like symptoms were induced in 7-week-old rats using
FGF8 as follows. FGF8 (50 μg/site, 50 μl of 1 mg/ml solution
in sterile saline) was injected into the right knee joint of each
rat (the FGF8 group). The anti-FGF8 antibody KM1334 was
dissolved in sterile saline at a concentration of 4 mg/ml.
KM1334 (20 mg/kg) was administered by intraperitoneal
injection 1 hour before the injection of FGF8 (the anti-FGF8
antibody group). For the vehicle group, sterile saline was
administered intraperitoneally instead of the antibody solution.
For the saline group, 50 μl sterile saline was injected into the
knee joint and sterile saline was administered intraperitoneally
instead of the antibody solution. Each group consisted of five
rats.
After 3 days, the inside of the knee articular capsule was
washed with 30 μl saline containing 0.38% sodium citrate,
and this washing liquid (synovial lavage fluid) was collected
according to the method of Yamada and colleagues [31]; this
procedure was repeated 10 times. The amount of S-GAG in
an aliquot was measured by the 1,9-dimethylmethylene blue
method. The patella of the knee joint was taken out and the
cartilaginous portion was digested with papain, and the weight
of the residual bone was measured according to a previous
report [32]. Briefly, papain was dissolved in 0.1 M sodium ace-
tate buffer (pH 5.8) containing 50 mM ethylenediamine
tetraacetic acid and then added to 5 mM L-cysteine hydrochlo-
ride monohydrate (final concentration of papain at 20 mg/ml).
The patella was incubated with 1 ml papain solution overnight
at 60°C. The residual bone was weighed.
Monoiodoacetic acid-induced arthritis in rats
The MIA-induced rat arthritis model was performed according
to previous reports [26]. MIA (Sigma-Aldrich) was dissolved at
10 mg/ml in sterile saline, and 25 μl solution was injected into
the right knee joint of 7-week-old rats. Each group consistedArthritis Research & Therapy    Vol 10 No 4    Uchii et al.
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of 10 animals. The anti-FGF8 antibody KM1334 was dissolved
in sterile saline to a final concentration of 4 mg/ml, and was
administered by intraperitoneal injection (20 mg/kg) 1 hour
before the injection of MIA. For the vehicle group, sterile saline
was administered intraperitoneally instead of the antibody
solution. In a saline group of animals, saline was injected in the
knee joint instead of the administration of MIA. After 3 days,
synovial lavage was performed to the knee articular capsule as
described above. The amount of S-GAG in the synovial lavage
fluid was measured by the 1,9-dimethylmethylene blue
method.
Statistical analysis
Data are presented as the mean ± standard error. The
Aspin–Welch test or Student's t test following the F test were
used for analysis of difference between two groups. Multiple
comparisons between control and treatment groups were
assessed by one-way analysis of variance, followed by the
Dunnett test. P < 0.05 was considered statistically significant.
All statistical calculations were performed with the Statistical
Analysis System (SAS Institute, Cary, NC, USA).
Results
Expression of FGF8 in the partial meniscectomized 
experimental osteoarthritis model
Arthritis was induced by partial meniscectomy in the rabbit
knee. Two weeks after the surgery, an accumulation of synovial
fluid was observed in the joint space of the meniscectomized
group. A representative histologic change of the meniscect-
omized joint is shown in Figure 1. Hyperplastic proliferation of
synovial cells, fibrosis, and infiltration of inflammatory cells
were observed in the joint space of meniscectomized knees
(Figure 1b and Table 1). In the normal group, no histological
changes were observed (Figure 1a and Table 1). In the menis-
cectomized group, synovial cells with positive staining for
FGF8 (Figure 1d, arrows) were increased as compared with
the normal group (Figure 1c and Table 1).
FGF8 was expressed in the fibroblasts after meniscectomy
(Figure 1d, arrowheads). In the normal group, very weak
expression of FGF8 was observed in synovial cells but not in
fibroblasts (Figure 1c). No positive reaction for FGF8 was
observed in the articular cartilage from both the normal group
and the meniscectomized group (Table 1). In the sham group,
synovial cells showed a weak positive reaction for FGF8 in
three out of four animals, and fibroblasts also showed a weak
positive reaction in all animals (Table 1). These findings sug-
gest that the expression of FGF8 was induced in synovia and
fibroblasts by mechanical injury.
Representative sections of cartilage in the normal group (Fig-
ure 1e) and in the meniscectomized group (Figure 1f) were
stained by safranin O. Reduction of cartilage and the presence
of clusters of chondrocytes occurred in the meniscectomized
group (Figure 1f). The severity of histological changes of the
articular cartilage was evaluated using a modified Mankin
scale (Table 1). The mean scores of the Mankin scale for the
meniscectomized group, for the sham group, and for the nor-
mal group were 6.0 ± 0.8, 0.5 ± 0.5, and 0.0 ± 0.0,
respectively.
Degradation of the extracellular matrix of chondrocytes 
by FGF8
To elucidate the role of FGF8 in meniscectomy-induced carti-
lage destruction, we investigated the activities of FGF8 on the
cultured chondrocytes. FGF8 dose-dependently induced
ECM degradation. The residual amounts of S-GAG in cultured
rabbit chondrocytes were 22.3, 21.0, 20.1, and 9.28 μg/well
Table 1
Histological findings of knee joints in the meniscectomized rabbit osteoarthritis model
Histological findings of synoviuma Meniscectomy group (n = 6) Sham group (n = 4) Normal group (n = 4)
0 1+ 2+ 3+ 4+ 0 1+ 2+ 3+ 4+ 0 1+ 2+ 3+ 4+
H&E staining
H y p e r p l a s i a  o f  s y n o v i a l  c e l l 0 0 5 1 0 1 03004 0000
F i b r o s i s  i n  c o n n e c t i v e  t i s s u e 0 0 1 5 0 0 01304 0000
I n f l a m m a t o r y  c e l l  i n f i l t r a t i o n  i n  c o n n e c t i v e  t i s s u e 4 0 1 1 0 4 00004 0000
KM1334 immunohistochemistryb
P o s i t i v e  r e a c t i o n s  i n  s y n o v i a l  c e l l s 0 6 0 0 0 1 30003 c 1000
P o s i t i v e  r e a c t i o n s  i n  f i b r o b l a s t i c  c e l l s 0 5 1 0 0 0 40004 0000
Positive reactions in cartilage 6c 0 0 0 0 4 00004 c 0000
Cartilage degeneration scorec (mean ± standard error) 6.0 ± 0.8 0.5 ± 0.5 0.0 ± 0.0
aHistological findings criteria: 0, non remarkable; 1+, very slight; 2+, slight, 3+, moderate; 4+, marked. bKM1334; an anti-FGF8 antibody. 
cSafranin O/fast green staining sample examined using the modified Mankin scale.Available online http://arthritis-research.com/content/10/4/R90
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at 0, 1, 10, and 100 ng/ml FGF8, respectively. The degrada-
tion of the ECM by 100 ng/ml FGF8 was inhibited dose-
dependently by anti-FGF8 antibody at 1 to 10 μg/ml (Figure
2a).
IL-1 is one of the important factors that promote cartilage deg-
radation. In the absence of FGF8, S-GAG in the ECM was not
decreased by the addition of a low concentration of IL-1α
(0.01 ng/ml). Upon incubation with IL-1α (0.01 ng/ml) and
FGF8 (100 ng/ml) for 48 hours, there was a significant
decrease in residual S-GAG compared with levels after FGF8
stimulation or IL-1α stimulation alone (Figure 2b). The
enhancement of IL-1α-induced S-GAG release by FGF8 was
concentration-dependently suppressed by the addition of anti-
FGF8 antibody at 1 to 10 μg/ml (Figure 2b).
Figure 1
Microphotographs of representative knee joints of meniscectomized  rabbits Microphotographs of representative knee joints of meniscectomized 
rabbits. Partial meniscectomy was performed on the rabbit knee to 
induce osteoarthritis-like morphology. Representative histologic sec-
tions of synovial membrane in (a) an untreated knee joint (normal) or (b) 
a meniscectomized knee joint were stained with H&E. Hyperplasia of 
synovial cells, fibrosis, and inflammatory cell infiltration was observed in 
the meniscectomized knee. Synovial membrane in (c) a normal knee 
joint or (b) a meniscectomized knee joint were immunostained with the 
anti-FGF8 antibody KM1334. Sections were reacted with horseradish 
peroxidase-labeled anti-mouse IgG, developed using diaminobenzidine 
(brown) and counter stained with hematoxylin (blue). Very weak stain-
ing of FGF8 was observed in a few synovial cells, but not in other tis-
sues in normal knee joints. (d) Many of the proliferated synovial cells 
(arrows) in meniscectomized knee joints showed positive reaction to 
FGF8. Positive staining of FGF8 was also observed in fibroblasts 
(arrowheads). (e) Normal and (f) meniscectomized articular cartilage 
was stained with safranin O. Reduction of safranin-O staining (red) and 
clusters of chondrocyte were observed in meniscectomized articular 
cartilage. Scale bar = 20 μm.
Figure 2
FGF8 induced the decrease in the sulfated glycosaminoglycan content  in the cellular matrix FGF8 induced the decrease in the sulfated glycosaminoglycan content 
in the cellular matrix. Chondrocytes were treated without (none) or with 
100 ng/ml FGF8 and/or 0.01 ng/ml IL-1α and various concentrations 
of anti-FGF8 antibody (Ab) for 48 hours. Sulfated glycosaminoglycan 
(S-GAG) content of the residual cellular matrix was measured using the 
1,9-dimethylmethylene blue method. Each column represents the mean 
± standard error. (a) FGF8 induced S-GAG degradation, which was 
concentration-dependently inhibited by anti-FGF8 antibody (1, 3 and 
10 μg/ml). Representative data of three independent experiments. $$$P 
< 0.001 compared with the no treatment group (Student's t test), ***P 
< 0.001 compared with FGF8 alone (Dunnett test). (b) Chondrocytes 
were treated with IL-1α (IL-1), FGF8, or IL-1α with FGF8 (IL-1 + 
FGF8). IL-1α enhanced FGF8-induced S-GAG degradation (IL-1 + 
FGF8). Anti-FGF8 antibody (1, 3 and 10 μg/ml) concentration-depend-
ently inhibited that degradation by FGF8 with IL-1α. Data from a single 
experiment are shown, but similar data were obtained in two additional 
experiments. ###P < 0.001 compared with the no treatment group 
(Student's t test), ++P < 0.01 compared with IL-1α alone 
(Aspin–Welch test), &&P < 0.01 compared with FGF8 alone (Student's 
t test), **P < 0.01 and ***P < 0.001 compared with the IL-1α + FGF8-
treated group (Dunnett test).Arthritis Research & Therapy    Vol 10 No 4    Uchii et al.
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Stimulation of proMMP-3 and prostaglandin E2 
production by FGF8 in rabbit chondrocytes
The effect of FGF8 on the release of proMMP-3 and PGE2 in
the culture medium was investigated. In the presence of FGF8
(100 ng/ml), production of proMMP-3 by rabbit chondrocytes
was significantly induced (P = 0.0079; Figure 3a). This indi-
cated that FGF8 may promote degradation of the ECM by pro-
duction of proteases including MMP-3. When anti-FGF8
antibody was added to the culture at 1 to 10 μg/ml, there was
a significant inhibition of proMMP-3 production.
PGE2 is a mediator of inflammation and pain. FGF8 signifi-
cantly increased the production of PGE2 from the chondro-
cytes (P = 0.0063; Figure 3b). The production of PGE2, which
was induced by FGF8, decreased dose-dependently in the
presence of anti-FGF8 antibody at 1 to 10 μg/ml (Figure 3b).
Promotion of growth of rabbit synovial cells by FGF8
The effects of FGF8 on synovial cells were assessed using pri-
mary cultures of rabbit synovial cells. FGF8 at 100 ng/ml sig-
nificantly promoted the growth of rabbit synovial cells as
measured by the incorporation of [3H]thymidine (Figure 4).
FGF8 at 100 ng/ml significantly promoted incorporation of
[3H]thymidine more than threefold compared with nonstimu-
lated cells (P < 0.0001). The addition of anti-FGF8 antibody
at 0.3 to 10 μg/ml significantly inhibited FGF8-induced incor-
poration of [3H]thymidine.
Articular destruction by intraarticular injection of FGF8 
into the rat knee joint
The activity of FGF8 on the knee joint was tested by the artic-
ular injection of FGF8 to rats. FGF8 dose-dependently
increased the release of S-GAG in joint fluid. The concentra-
tions of S-GAG were 3.96, 6.35, 12.2, and 16.5 μg/ml by 0,
0.5, 5, and 50 μg/site FGF8, respectively. An injection of 50
μg/site FGF8 increased the concentration of S-GAG in joint
fluid (Figure 5a). The amount of S-GAG in the FGF8 injection
group was 4.2 times higher than that of the saline injection
group (P < 0.0001). Anti-FGF8 antibody significantly inhibited
the degradation of GAG in the FGF8-treated joints by 33% (P
= 0.036). These data indicate that the injection of FGF8
causes degradation of the ECM of the articular cartilage and
release of S-GAG into the synovial fluid. In addition, the injec-
tion of FGF8 decreased the bone weight of the patella to 43%
Figure 3
FGF8 enhanced the release of promatrix metalloproteinase-3 and pros- taglandin E2 from rabbit articular chondrocyte cultures FGF8 enhanced the release of promatrix metalloproteinase-3 and pros-
taglandin E2 from rabbit articular chondrocyte cultures. Chondrocytes 
were treated without (none) or with 100 ng/ml FGF8 and various con-
centrations of anti-FGF8 antibody (Ab) (1, 3 and 10 μg/ml) for 48 
hours. Concentrations of (a) promatrix metalloproteinase-3 (proMMP-
3) and (b) prostaglandin E2 (PGE2) in the culture medium were deter-
mined by ELISA. Each column represents the mean ± standard error. 
Representative data of two or three independent experiments. ##P < 
0.01 compared with the no treatment group (Aspin–Welch test), ***P < 
0.001 compared with FGF8 alone (Dunnett test).
Figure 4
FGF8 induced the growth of rabbit synovial fibroblast-like cells FGF8 induced the growth of rabbit synovial fibroblast-like cells. Rabbit 
synovial fibroblast-like cells were treated without (none) or with 100 ng/
ml FGF8 and various concentrations of anti-FGF8 antibody (Ab) (0.1, 
0.3, 1, 3 and 10 μg/ml) for 72 hours. [3H]Thymidine incorporation dur-
ing the last 24-hour pulse of cultures was determined. Each column 
represents the mean ± standard error. Data from a single experiment 
are shown, but similar data were obtained in three additional experi-
ments. ###P < 0.001 compared with the no treatment group (Student's 
t test), ***P < 0.001 compared with FGF8 alone (Dunnett test).Available online http://arthritis-research.com/content/10/4/R90
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of the saline injection group (P < 0.0001; Figure 5b). Anti-
FGF8 antibody attenuated bone loss in the FGF8-treated
joints by 34%, although this was not statistically significant.
Evaluation of anti-FGF8 antibody in a monoiodoacetic 
acid-induced rat arthritis model
Injection of MIA, an inhibitor of glycolysis, into the femorotibial
joint of rats promotes loss of articular cartilage similar to that
noted in human OA. The injection of MIA increased the con-
centration of S-GAG in the joint space of rats (Figure 6). The
amount of S-GAG release in the MIA group was 1.6 times
higher than that in the saline injection group (P = 0.0014; Fig-
ure 6). These data show that MIA promotes the degradation of
the ECM of the articular cartilage and the release of S-GAG
into synovial fluid. Intraperitoneal administration of anti-FGF8
antibody significantly inhibited the increase in S-GAG in the
joint by 42% (P = 0.0188; Figure 6).
Discussion
The present study provides new and interesting findings about
the role of FGF8 in joint inflammation. We analyzed the rabbit
knee in a partial meniscectomized model to clarify the expres-
sion of FGF8 – which was very slightly expressed or not
expressed in normal joints. Two weeks after meniscectomy,
the cartilage from the lateral femoral condyle and from the
lateral tibial plateau of meniscectomized animals showed
degenerative changes that were similar to those observed in
human OA. In the meniscectomized group, FGF8 was
expressed on proliferated synovial cells and fibroblasts, but
expression of FGF8 was absent or minimal in normal joints.
Figure 5
Intraarticular injection of FGF8 induced the sulfated glycosaminoglycan release in knee joints and destruction of patella Intraarticular injection of FGF8 induced the sulfated glycosaminoglycan release in knee joints and destruction of patella. Fifty micrograms of FGF8 
was injected into the knee joint of rats (vehicle). KM1334 (the anti-FGF8 antibody (Ab)) was intraperitoneally administered before the injection of 
FGF8. For the saline injection group (saline), 50 μl sterile saline was injected into the knee joint. Synovial lavage was performed with saline 3 days 
after the FGF8 injection. (a) Sulfated glycosaminoglycan (S-GAG) content in the synovial lavage fluid was measured by the 1,9-dimethylmethylene 
blue method. (b) The cartilaginous portion of the patella was digested with papain to measure the weight of the residual bone. Each column repre-
sents the mean ± standard error (n = 5). ###P < 0.001 compared with the saline group (Student's t test), *P < 0.05 compared with the vehicle 
group (Aspin–Welch test).
Figure 6
Effect of FGF8 on monoiodoacetic acid-induced sulfated gly- cosaminoglycan release in the knee joint of rats Effect of FGF8 on monoiodoacetic acid-induced sulfated gly-
cosaminoglycan release in the knee joint of rats. Monoiodoacetic acid 
(MIA) was injected into the right knee joint of rats (vehicle). KM1334 
(the anti-FGF8 antibody (Ab)) was intraperitoneally administered before 
the injection of MIA. As a control, sterile saline was injected into the 
knee instead of MIA (saline). The synovial lavage was performed with 
saline 3 days after the intraarticular injection of MIA into knee joints. The 
content of sulfated glycosaminoglycan (S-GAG) in an aliquot was 
measured by the 1,9-dimethylmethylene blue method. Each column 
represents the mean ± standard error (n = 10). ##P < 0.01 compared 
with the sham group (Aspin–Welch test), *P < 0.05 compared with the 
vehicle group (Aspin–Welch test).Arthritis Research & Therapy    Vol 10 No 4    Uchii et al.
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which the ligaments were resected and the articular spaces
were exposed (the sham group). These data indicate that
expression of FGF8 is induced by chronic joint injury.
Degradation of the ECM was promoted in the presence of
FGF8. The function of FGF8 on cartilage destruction was
examined using a primary culture of rabbit chondrocytes. Rab-
bit articular chondrocytes are useful to detect biological
responses. In the present study, we used primary culture of
chondrocytes from 3-week-old rabbits according to the previ-
ous report [33]. IL-1-induced matrix degradation according to
the induction of metalloproteases was reported in cultured
chondrocytes from 300 to 500 g young rabbit [33]. Articular
chondrocytes from 4-week-old rabbits underwent more dou-
bling in vitro compared with those from 3.5-year-old adult rab-
bits, but showed no difference in shape at primary culture [34].
FGF8 induced the production of proMMP-3 by cultured
chondrocytes, and anti-FGF8 antibody attenuated the release
of these factors. MMP-3 plays an important role in cartilage
degradation [3,4] and is a major factor in the catabolism of car-
tilage macromolecules. MMP-3 resolves proteoglycan in the
ECM and also activates the other MMPs that participate in the
degradation of the matrix in joints. MMP-3 is increased both in
cartilage and in synovial membranes from OA patients [35]. In
our study, FGF8 induced the production of proMMP-3 and
significantly decreased the residual amount of S-GAG in the
ECM in cultured chondrocytes. These data indicate that FGF8
can promote the destruction of articular cartilage by the induc-
tion of factors such as MMP-3 and PGE2 in joints.
FGF8 and IL-1 synergistically accelerated the degradation of
the ECM. The participation of synovial inflammation in the pro-
gression of cartilage changes at the clinical stage of OA is
becoming increasingly obvious [1]. A number of clinical stud-
ies demonstrate a clear association between inflammation and
disease progression [36]. A large number of inflammatory fac-
tors, such as IL-1 and TNFα, are synthesized within inflamed
synovium and play an important role in articular destruction in
OA [1]. In cultured chondrocytes, degradation of the ECM
induced by FGF8 was further enhanced by a small amount of
IL-1. Anti-FGF8 antibody blocked this FGF8 with IL-1-induced
degradation of the ECM. IL-1 causes both matrix degradation
and downregulation of proteoglycan synthesis [37], but further
studies are required to clarify whether FGF8 also downregu-
lates ECM synthesis.
FGF8 induced the production of PGE2 from cultured chondro-
cytes. PGE2 is the major prostaglandin in the synovial fluid of
OA patients, and is produced by IL-1-stimulated chondrocytes
and synoviocytes from OA patients [37]. Cartilage specimens
from OA patients spontaneously release more PGE2  than
does normal cartilage [38]. Nonsteroidal antiinflammatory
drugs, including cyclooxygenase-2 inhibitors, are commonly
used to control pain and inflammation in OA [1]. These drugs
inhibit the production of PGE2 and consequently relieve pain
caused by PGE2. In the present study, a low concentration of
anti-FGF8 antibody markedly inhibited the production of PGE2
by cultured chondrocytes. Anti-FGF8 antibody might be
expected to provide an analgesic effect because it inhibits
PGE2 production by chondrocytes.
FGF8 induced joint destruction in vivo. Injection of FGF8 into
the rat knee joints promoted the release of S-GAG from carti-
lage into the synovial fluid. Following injection of FGF8, the
weight of the patella was reduced. Further study is required to
determine whether FGF8 induces morphological change as
shown in OA. Many of the etiologic factors responsible for OA
are related to the breakdown of extracellular macromolecules.
FGFs are one of the candidates that cause progression of OA
[39]. FGF2 has various physiological effects on bone and car-
tilage metabolism [40]. FGF2, which is expressed ubiquitously
in mesodermal and neuroectodermal cells, has various physio-
logical functions. In the present study, we have demonstrated
that FGF8 is selectively expressed in injured joints. Cartilage
degradation is induced by exogenous FGF8. These results
indicate that FGF8 is one of the selective mediators of arthritis.
FGF8 is involved in the process of limb and facial morphogen-
esis [17]. Further studies are required of whether FGF8 has a
physiological function in maturing of joints and diseases in
children such as juvenile rheumatoid arthritis.
FGF8 is expressed in synovial cells and concentration-
dependently enhances growth of cultured synovial cells. It is
possible that FGF8 promotes growth of synovial cells via auto-
crine signaling. FGF8 also induced degradation of the ECM in
cultured chondrocytes. These studies suggest that the injury
of synovia induces the expression of FGF8 in the joint, and this
may promote degradation of cartilage via a paracrine system.
The bone weight of the patella was decreased following an
injection of FGF8 into the rat joint. Synovial hyperplasia is
known to initiate bone and cartilage erosions [1]. Bone degra-
dation following intraarticular injection of FGF8 may therefore
be due to the growth of synovial cells and also production of
various factors from synoviocytes, fibroblasts, or other cells.
FGF8 can induce cartilage and bone degradation to cause the
arthritis-like syndromes and possibly aggravate the pathology
of OA. Other factors such as mechanical stress, cytokines,
and inflamed cells are also important for cartilage degenera-
tion. Further studies are required to elucidate the contribution
of FGF8 on bone absorption and joint destruction.
Anti-FGF8 antibody not only reduced cartilage degradation
induced by the injection of FGF8 in the joints, but also
decreased cartilage degradation in the MIA-induced rat arthri-
tis model. These data indicate that systemic application of anti-
FGF8 antibody protects the FGF8-dependent cartilage degra-
dation. The use of MIA to chemically induce degenerative
arthritis was first described by Kalbhen and Blum [41], and
subsequently by other investigators [26]. The injection of MIA
into the knees of rats provides a model where lesions resem-Available online http://arthritis-research.com/content/10/4/R90
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ble some aspects of human OA. The amounts of MMP were
significantly elevated after the injection of MIA. This model has
been used for the development of chondroprotective drugs
[26]. Anti-FGF8 antibody inhibited release of S-GAG in the
MIA-induced arthritis model. Anti-FGF8 antibody suppressed
the production of proMMP-3 and PGE2  from cultured
chondrocytes. These findings provide evidence for the poten-
tial use of anti-FGF8 antibody in the treatment of articular tis-
sue degradation and pain in OA. An anti-FGF8 antibody is
expected to attenuate the symptoms of rheumatoid arthritis.
We are studying the effects of anti-FGF8 antibody on colla-
gen-induced arthritis and on adjuvant-induced arthritis.
Conclusion
We have demonstrated that the expression of FGF8 on syno-
via is increased in an experimental model of OA in rabbits.
FGF8 induced production of MMP-3 and PGE2, and caused
degradation of the ECM in vitro. Degradation of S-GAG was
detected by intraarticular injection of FGF8 in rats. Anti-FGF8
antibody attenuates the destruction of cartilage in the MIA-
induced arthritis model. These data indicate that FGF8 has a
possible pathophysiological role in the degradation of carti-
lage in OA models.
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